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Periostin and Mesothelin: Potential
Predictors of Malignant Progression in
Intrahepatic Cholangiocarcinoma
SEE ARTICLE ON PAGE 155
Cholangiocarcinoma (CCA), a heterogeneousgroup of malignancy arising at any level of thebiliary tree based on their anatomical location,
is classiﬁed into intrahepatic (iCCA), perihilar, and
distal subtypes. iCCA, which arises distally to the
second-order bile ducts, is a highly heterogeneous and
aggressive malignancy with overall poor prognosis. The
rate of iCCA is increasing rapidly, particularly in West-
ern countries; however, its precise etiology and patho-
genesis remain elusive.(1) While surgical resection is the
ﬁrst line of treatment, liver transplantation is the poten-
tial curative treatment for unresectable tumors in
patients with iCCA, and posttransplantation 5-year sur-
vival rates are 51% in these patients. Currently, there are
no curative medical therapies or targeted molecular ther-
apies approved for use in iCCA. The complex plethora
of cell types, extracellular matrix, and soluble factors that
inﬂuence tumor progression should be considered to
understand its pathogenesis and to devise effective strat-
egies for its clinical management.(1) Furthermore, identi-
ﬁcation of biomarker signatures relevant to disease
progression and aggressiveness may not only aid in diag-
nosis but also have prognostic value that will help build a
precision approach for the treatment of iCCA.
Recent studies exploring mechanisms related to iCCA
progression have focused on the role of cancer stem cells,
mesenchymal stem cells, and microRNAs in driving
iCCA progression.(2) Additional mechanisms related to
iCCA development have investigated genetic alterations
as well as molecular aberrations that include the signiﬁ-
cance of ﬁbroblast growth factor signaling, hepatocyte
growth factor–mesenchymal epithelial transition signal-
ing, myeloid leukemia cell differentiation protein-1
(Mcl-1), Kirsten sarcoma virus oncogene (KRAS), and the
phoshoinositide-3-kinase–protein kinase B–mammalian
target of rapamycin complex pathway as well as meso-
thelin expression.(3) Immune checkpoint proteins pro-
grammed cell death protein 1 (PD-1) and programmed
death-ligand 1 (PD-L1), which have also been explored
in surgically resected iCCA specimens, showed high
expression, suggesting a potential for exploiting these
pathways/inhibitors for therapeutic regimens.
The stroma of iCCA undergoes profound changes
in its composition during cholangiocarcinogenesis and
modulates the biology of epithelial tumor cells.(3) Cells
endowed in CCA stroma, comprising mainly cancer-
associated ﬁbroblasts, tumor associated macrophages,
and vasculature cells, contribute to tumor mass
Abbreviations: 3D, three-dimensional; CCA, cholangiocarcinoma;
EMT, epithelial–mesenchymal transition; iCCA, intrahepatic
cholangiocarcinoma.
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formation and signiﬁcantly affect iCCA biology.(1)
Considering the desmoplastic nature of iCCA and its
origin in chronic inﬂammatory conditions, the role of
extracellular matrix proteins in driving pathogenesis
cannot be undermined. Matricellular glycoproteins,
such as periostin and mesothelin, have been under
investigation for their contribution to the progression of
iCCA, and hence their prognostic value as biomarkers
to determine aggressiveness and invasiveness is
emerging.(4,5)
In Hepatology Communications, Manzanares et al.(6)
investigated the modulation of periostin and mesothe-
lin, predictors of poor survival for patients with iCCA,
in tumor progression in an orthotropic tumor model in
rat and in a three-dimensional (3D) culture model.
The authors found a strong positive correlation
between tumor and serum periostin and mesothelin
and increasing liver tumor mass and associated perito-
neal metastases but also provided data in vitro showing
these markers reﬂected differences in CCA cell aggres-
siveness and malignant grade. Expression levels of
periostin and its pattern were most prominent in the
desmoplastic stroma of larger sized more aggressive
liver tumors and peritoneal metastases. In comparison,
mesothelin was more highly expressed in CCA cells.
The results of in situ expression reﬂected that serum
levels of both biomarkers positively and linearly corre-
lated with signs of aggressiveness.
Periostin is a crucial extracellular remodeling factor
and in cancer cells binds to integrins leading to
activation of phoshoinositide-3-kinase–protein kinase
B-mediated and focal adhesion kinase-mediated sig-
naling, resulting in invasion, metastasis, cell survival,
and epithelial–mesenchymal transition (EMT).(4) Pre-
vious observations reported increased periostin staining
in human surgically resected iCCA, and this was asso-
ciated with poor prognosis, which has been noted in
other cancers, including pancreatic and breast tumors.
Further studies evaluating the molecular mechanisms
of periostin related to cancer progression and invasion
could provide promise to develop this glycoprotein as a
biomarker and/or therapeutic target.
Mesothelin, another glycoprotein important in
extracellular matrix modeling has also been suggested
for its potential as a prognostic marker in human
iCCA.(5) Increased mesothelin expression has been
associated with shorter postoperative survival outcomes
in iCCA.(5) Because all previous studies relied on
immunostaining to score expression in human tumors,
Manzanares et al.(6) designed a systematic investigation
of mesothelin, using an orthotopic tumor model of
iCCA and 3D cultures of CCAs. Interestingly,
increased serum mesothelin correlated with size of the
orthotopic iCCA tumor. Remarkably, Manzanares
et al. identiﬁed two molecular weight forms of meso-
thelin in iCCA tumors. The 50-kDa mesothelin,
expressed predominantly at the apical luminal surface,
is predictive of a more differentiated less aggressive
iCCA phenotype. On the other hand, the 40-kDa
cytoplasmic mesothelin is associated with increased
malignant progression. Complementary to these in
vivo studies, in vitro 3D cultures showed that cocultur-
ing of a-smooth muscle actin-positive cancer-associ-
ated ﬁbroblasts contributed to an increase in the 40-
kDa mesothelin form and correlated with an increase
in iCCA anaplasia and ductal-like cell polarity. The
precise mechanisms that inﬂuence expression of the
40-kDa cytoplasmic mesothelin associated with malig-
nancy remains to be determined. Future extensive
characterization is justiﬁed to determine the relevance
of the two molecular weight forms in human iCCA.
Given the complexity in diagnosis of iCCA and lack
of therapeutics, identifying molecular markers that not
only contribute to pathogenesis but also serve as poten-
tial biomarkers or therapeutic targets is an attractive
premise. The in vivo and in vitro results described by
Manzanares et al.(6) guarantee additional work using
clinical samples of iCCA but also perihilar and distal
CCA to provide a scientiﬁc and clinical basis for future
development of periostin and/or mesothelin as diag-
nostic and prognostic markers. More importantly,
understanding the role of periostin and mesothelin in
EMT and cancer progression could not only uncover
their function but also provide support for a future
basis of targeting EMT for cancer treatment.
EMT is an important event that occurs during
metastasis and is essential in the migration and inva-
sion of cancer cells from the primary site. This transi-
tion of tumor epithelial cells is accompanied by genetic
reprogramming, guided by the main EMT-inducing
transcription factors SNAIL, TWIST, and ZEB, with
repression of genes of the epithelial phenotype and
acquisition of mesenchymal markers, such as a-smooth
muscle actin, vimentin, and ﬁbronectin. The prognos-
tic value of different EMT markers has been analyzed
in CCA.(8) For example, nuclear expression of the
S100A4 mesenchymal marker by neoplastic ducts was
a strong predictor of metastasis and reduced survival in
patients with CCA undergoing surgical resection. The
modulation of EMT is a candidate strategy to counter-
act cancer local invasiveness and metastases, although
to develop an effective anti-EMT treatment,
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redundancies and bypasses among the pathways regu-
lating EMT should be addressed.(7)
Whether periostin regulates the induction of EMT
and hence malignant progression as well as metastasis
is unknown. Interestingly, Mino et al.(8) investigated
the role of periostin in regulating EMT in iCCA.
These studies provide a functional basis for periostin in
iCCA and unravel its crucial role in pathogenesis.
Mino et al. showed that periostin is highly expressed
in surgically resected human iCCA tumors compared
to adjacent nontumor tissue. Importantly, increased
periostin expression in undifferentiated iCCA cell lines
compared to moderately differentiated iCCA cell lines
suggests that periostin expression correlates to the
malignant potential of iCCA. Further, pronounced
release of periostin from undifferentiated iCCA cells
compared to moderately differentiated iCCA cells sup-
ports its role in malignancy. In fact, knockdown of
periostin in undifferentiated iCCA cells exhibits
decreased EMT markers and up-regulation of epithe-
lial markers, suggesting reversal of EMT and reduction
of the malignant potential, including diminished inva-
sion and migration. These studies unravel a role for
periostin in EMT and the malignant potential of
iCCA, reinforcing its potential as a biomarker of
tumor progression and poor prognosis.
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